Evidence Hub

Global Prevalence of Neurological Manifestations Among Patients Hospitalized with COVID-19: A Report of the Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID) and the European Academy of Neurology [ENERGY] Registry Collaborative

S. Chou, E. Beghi, R. Helbok, E. Moro, J. Sampson, Valeria Altamirano, S. Mainali, C. Bassetti et al.

2021

3,744 participants · 6 citations

Abstract

Background: The novel coronavirus disease 2019 (COVID-19) pandemic continues to affect millions globally, with increasing reports of COVID-19 neurological manifestations but limited data on their population prevalence and outcome. This is the first report from two international consortia studies aimed to determine the neurological phenotypes, prevalence, and outcomes among hospitalized COVID-19 patients.

Methods: The Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID) is a multi-center cohort study enrolling consecutive hospitalized COVID-19 patients to determine type, prevalence, and outcomes of COVID-19 neurological manifestations. The European Academy of Neurology (EAN) Neuro-COVID Registry (ENERGY) is a global registry to capture COVID-19 neurological manifestations and outcomes. Using harmonized data elements across two consortia, this is the first report describing 3744 subjects from 28 centers, representing 13 countries and 4 continents.

Findings: Data are presented from three separate cohorts: the GCS-NeuroCOVID “ALL COVID” cohort (n=3055), which includes consecutive hospitalized COVID-19 patients with and without neurological manifestations, the GCS-NeuroCOVID “COVID NEURO” cohort (n=475), consisting of consecutive hospitalized COVID-19 patients with confirmed neurological manifestations, and the ENERGY cohort (n=214), which includes COVID-19 patients with a neurological consultation. Across cohorts, neurological manifestations are present…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 3,744 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free